オンライン配信アーカイブ

2) A Phase 1 Clinical Trial to evaluate the Safety and Tolerability of Schwann-like cells for Charcot–Marie–Tooth type 1 (CMT1)

Jaeseung Lim (Cellatoz Therapeutics)